RKRichard Klaus

Richard Klaus

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Richard Klaus has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • From prematurity and low birth weight to CKD: opportunities for intervention

    by Richard Klaus, Bärbel Lange-Sperandio

    Preterm birth (<37 completed gestational weeks), low birth weight (<2500 g) and small for gestational age (SGA, birth weight <10th percentile for gestational age) are interrelated neonatal phenotypes that adversely affect lifelong kidney health. They have been grouped under the term small vulnerable newborn (SVN). Being born as SVN ranks fifth among risk factors for early mortality and imposes a lifelong susceptibility for chronic kidney disease (CKD). The combination of extreme prematurity and SGA triples CKD risk in early adulthood. Globally, around 35 million SVN are born annually which will contribute to rising CKD morbidity and mortality. In SVN, nephron mass is reduced because prematurity interrupts and an adverse intrauterine environment impairs nephron endowment. Maladaptive responses to low nephron mass include glomerular hyperfiltration, glomerular hypertension and glomerular sclerosis. In addition, complications of prematurity cause renal hypoperfusion and pharmacological treatment on the neonatal intensive care unit (NICU) can be nephrotoxic, both contributing to neonatal acute kidney injury (AKI). Neonatal AKI is common, has a high acute mortality and is a potentially modifiable second hit towards CKD. Preventive strategies include optimizing maternal health to prevent SVN, improved detection and avoidance of neonatal AKI by reduction of nephrotoxicity and kidney hypoperfusion during NICU-treatment and systematic documentation of AKI at discharge. Physicians and families should be educated about the child’s lifelong CKD risk. Follow-up should be stratified by completed gestational weeks, birth weight, occurrence of AKI and comorbidities. Follow-up aims are early identification and treatment of CKD progression factors and complications.

  • Outcome of rituximab treatment in children with non-dialysis-dependent anti-GBM disease

    by Richard Klaus, Nele Kanzelmeyer, Dieter Haffner, Bärbel Lange-Sperandio

    Background Anti-GBM disease is a rare vasculitis mediated by pathogenic antibodies against collagen IV. Anti-GBM disease presents with rapid progressive glomerulonephritis and leads to kidney failure if untreated. KDIGO recommends plasma exchanges (PEX) for antibody elimination and steroids plus cyclophosphamide (CTX) to suppress antibody production. CTX is associated with severe side effects including gonadal toxicity. Rituximab (RTX) and mycophenolate mofetil (MMF) might be a less toxic but equally efficient alternative to CTX. Studies in pediatric anti-GBM disease patients receiving RTX and MMF instead of CTX are lacking. Methods A retrospective survey in 8 tertiary German centers was performed. The clinical data of patients diagnosed between 2014 and 2022 were collected and analyzed. Results Five adolescent patients treated with PEX and RTX and/or MMF due to anti-GBM disease were analyzed. All patients had anti-GBM antibodies, hematuria, glomerular proteinuria, and pulmonary hemorrhage. eGFR was 124 ml/min/1.73 m2 (range 47–162), and all patients were non-dialysis-dependent but with relevant histological kidney affection (mean crescents on kidney biopsy 77%). Antibody clearance was achieved after 13 PEX cycles (range 6–31). Four out of 5 patients received methylprednisolone pulses. All patients received oral prednisolone and MMF, and four patients received a median of 4 RTX doses (range 2–4). After a mean follow-up of 27 months, 4/5 patients had conserved or improved kidney function, while one patient (20%) developed kidney failure. Conclusions In this small series of pediatric non-dialysis-dependent anti-GBM disease patients, first-line treatment with RTX and MMF showed a favorable kidney outcome in 4/5 cases and had an acceptable side effect profile. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information


  • Open Access

    Comparison of clean catch and bag urine using LC–MS/MS proteomics in infants

    by Richard Klaus, Teresa K. Barth, Axel Imhof, Franziska Thalmeier, Bärbel Lange-Sperandio

    Background: Urinary proteomics identifies the totality of urinary proteins and can therefore help in getting an early and precise diagnosis of various pathological processes in the kidneys. In infants, non-invasive urine collection is most commonly accomplished with a urine bag or clean catch. The influence of those two collection methods on urinary proteomics was assessed in this study. Methods: Thirty-two urine samples were collected in infants using urine bag and clean catch within 24 h. Nine boys and seven girls with a mean age of 4.3 ± 2.9 months were included (5 × post-pyelonephritis, 10 × non-kidney disease, 1 × chronic kidney disease (CKD)). Liquid chromatography-mass spectrometry (LC–MS/MS) was performed in data-independent acquisition (DIA) mode. Protein identification and quantification were achieved using Spectronaut. Results: A total of 1454 urinary proteins were detected. Albumin and α-1-microglobulin were detected the most. The 18 top-abundant proteins accounted for 50% of total abundance. The number of proteins was slightly, but insignificantly higher in clean catch (957 ± 245) than in bag urine (876 ± 255). The median intensity was 1.2 × higher in the clean catch. Overall, differential detection of proteins was 29% between the collection methods; however, it diminished to 3% in the 96 top-abundant proteins. Pearson’s correlation coefficient was 0.81 ± 0.11, demonstrating a high intraindividual correlation. A principal component analysis and a heat map showed clustering according to diagnoses and patients rather than to the collection method. Conclusion: Urinary proteomics shows a high correlation with minor variation in low-abundant proteins between the two urine collection methods. The biological characteristics overrule this variation.


  • Open Access

    Chronic Kidney Disease in Boys with Posterior Urethral Valves–Pathogenesis, Prognosis and Management

    by Richard Klaus, Bärbel Lange-Sperandio

    Posterior urethral valves (PUV) are the most common form of lower urinary tract obstructions (LUTO). The valves can be surgically corrected postnatally; however, the impairment of kidney and bladder development is irreversible and has lifelong implications. Chronic kidney disease (CKD) and bladder dysfunction are frequent problems. Approximately 20% of PUV patients will reach end-stage kidney disease (ESKD). The subvesical obstruction in PUV leads to muscular hypertrophy and fibrotic remodelling in the bladder, which both impair its function. Kidney development is disturbed and results in dysplasia, hypoplasia, inflammation and renal fibrosis, which are hallmarks of CKD. The prognoses of PUV patients are based on prenatal and postnatal parameters. Prenatal parameters include signs of renal hypodysplasia in the analysis of fetal urine. Postnatally, the most robust predictor of PUV is the nadir serum creatinine after valve ablation. A value that is below 0.4 mg/dL implies a very low risk for ESKD, whereas a value above 0.85 mg/dL indicates a high risk for ESKD. In addition, bladder dysfunction and renal dysplasia point towards an unbeneficial kidney outcome. Experimental urinary markers such as MCP-1 and TGF-β, as well as microalbuminuria, indicate progression to CKD. Until now, prenatal intervention may improve survival but yields no renal benefit. The management of PUV patients includes control of bladder dysfunction and CKD treatment to slow down progression by controlling hypertension, proteinuria and infections. In kidney transplantation, aggressive bladder management is essential to ensure optimal graft survival.


  • Blood pressure in children with renal cysts and diabetes syndrome

    by Tomáš Seeman, Friederike Weigel, Kveta Blahova, Filip Fencl, Stepanka Pruhova, Katharina Hermes, Richard Klaus, Bärbel Lange-Sperandio, Veit Grote, Ulrike John-Kroegel

    Cystic kidney diseases such as autosomal recessive or dominant polycystic kidney disease (ARPKD and ADPKD) are associated with high prevalence of arterial hypertension. On the contrary, studies on hypertension in children with renal cysts and diabetes (RCAD) syndrome caused by abnormalities in the HNF1B gene are rare. Therefore, the primary aim of our study was to investigate the prevalence of high blood pressure in children with RCAD syndrome due to HNF1B gene abnormalities and secondary to search for possible risk factors for development of high blood pressure. Data on all children with genetically proven RCAD syndrome from three pediatric nephrology tertiary centers were retrospectively reviewed (office blood pressure (BP), ambulatory blood pressure monitoring (ABPM), creatinine clearance, renal ultrasound, echocardiography, albuminuria/proteinuria). High blood pressure was defined as BP ≥ 95th percentile of the current ESH 2016 guidelines and/or by the use of antihypertensive drugs. Thirty-two children with RCAD syndrome were investigated. Three children received ACE inhibitors for hypertension and/or proteinuria. High blood pressure was diagnosed using office BP in 22% of the children (n = 7). In the 7 performed ABPM, 1 child (14%) was diagnosed with hypertension and one child with white-coat hypertension. Creatinine clearance, proteinuria, albuminuria, body mass index, enlargement, or hypodysplasia of the kidneys and prevalence of HNF1B-gene deletion or mutation were not significantly different between hypertensive and normotensive children. Conclusion: High blood pressure is present in 22% of children with RCAD syndrome. What is Known: • Arterial hypertension is a common complication in children with polycystic kidney diseases. What is New: • High office blood pressure is present in 22% and ambulatory hypertension in 14% of children with renal cyst and diabetes (RCAD) syndrome.